中药复方辅助抗组胺药治疗慢性自发性荨麻疹:疗效、复发与安全性的网状Meta分析
该网状Meta分析纳入50项随机对照试验共5814例慢性自发性荨麻疹患者,比较二代抗组胺药单用或联用经典中药复方的疗效、复发与安全性。多数中药复方联合方案在SSRI≥90%和≥60%结局上优于抗组胺药单药,当归饮子、玉屏风散和桂枝汤组合疗效排名靠前;氯雷他定或依巴斯汀联合当归饮子降低复发风险最明显,长疗程亚组更显著。部分联合方案可降低不良事件风险。
要点
- 多数经典中药复方联合二代抗组胺药在症状改善上优于抗组胺药单药治疗。
- 当归饮子、玉屏风散、桂枝汤联合方案疗效排名靠前,氯雷他定或依巴斯汀联合当归饮子降低复发最明显。
- 部分联合方案可降低不良事件风险,但疗效证据确定性多为中等,安全性证据确定性较低。
核心结论
- 经典中药复方(尤其当归饮子、玉屏风散、桂枝汤)联合二代抗组胺药可能改善慢性自发性荨麻疹的缓解并降低复发,且不增加不良事件发生率。
研究设计与样本
- 系统检索并纳入50项随机对照试验,共5814例慢性自发性荨麻疹患者,采用贝叶斯与频率学网状Meta分析。
- 主要结局为基于症状评分下降指数(SSRI)的临床改善,次要结局包括复发率和不良事件。
- 使用RoB 2.0评估偏倚风险,CINeMA框架评价证据确定性。
主要发现
- 多数经典中药复方联合方案在SSRI≥90%和SSRI≥60%结局上优于抗组胺药单药治疗。
- 当归饮子、玉屏风散和桂枝汤相关联合方案在疗效排名中 consistently 位居前列。
- 氯雷他定或依巴斯汀联合当归饮子降低复发风险最明显,长疗程亚组(>12周)效果更显著。
- 西替利嗪联合当归饮子、氯雷他定联合桂枝汤等方案与不良事件风险降低相关。
- 所有评估治疗在降低IgE或IL-4水平方面均未显示优于西替利嗪单药的统计学显著优势。
关键数值与推荐
- 疗效结局的证据确定性以中等为主,安全性结局的总体证据确定性较低。
- 复发风险降低在长疗程亚组(>12周)中更明显。
临床怎么用
- 对二代抗组胺药控制不佳的慢性自发性荨麻疹患者,可考虑联合当归饮子、玉屏风散或桂枝汤以提高缓解率并降低复发。
- 联合方案未增加不良事件风险,部分组合(如西替利嗪联合当归饮子、氯雷他定联合桂枝汤)可能降低不良事件风险。
- 长疗程(>12周)联合治疗可能更有利于降低复发风险。
局限性
- 疗效证据确定性多为中等,安全性证据确定性较低,需进一步高质量头对头试验确认。
- 未发现联合方案在降低IgE或IL-4水平方面优于西替利嗪单药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic spontaneous urticaria (CSU) presents treatment challenges despite second-generation antihistamines (sgAHs) serving as the first-line therapy. PURPOSE: The aim of this network meta-analysis is to systematically evaluate the efficacy hierarchy and safety profile of classical traditional Chinese medicine (TCM) formulas used as adjuncts to antihistamines. METHODS: We systematically evaluated 50 randomized controlled trials involving 5,814 patients using both Bayesian and frequentist network meta-analyses (NMAs) to compare the efficacy, recurrence, and safety of sgAHs alone or in combination with classical TCM formulas. The primary outcome was clinical improvement based on the Symptom Score Reducing Index (SSRI), with secondary outcomes including recurrence rates and adverse events (AEs). Risk of bias was assessed using RoB 2.0, and evidence certainty was evaluated using the CINeMA framework. Bayesian and frequentist NMA approaches were employed. Sensitivity analyses were conducted based on the study quality and prescription modifications. RESULTS: Most combination regimens of classical TCM formulas were superior to antihistamine monotherapy for both SSRI ≥90% and ≥60% outcomes. Combinations involving Danggui Yinzi, Yupingfeng powder, and Guizhi decoction consistently ranked among the top in terms of efficacy. Among these regimens, loratadine or ebastine combined with Danggui Yinzi demonstrated the most pronounced reduction in recurrence risk, with the effect being more evident in the long-course subgroup (>12 weeks). Certain combination regimens, such as cetirizine combined with Danggui Yinzi and loratadine combined with Guizhi decoction, were associated with a reduced risk of AEs. However, no evaluated treatment showed a statistically significant advantage over cetirizine monotherapy in reducing IgE or IL-4 levels. The certainty of evidence for efficacy outcomes was predominantly moderate, whereas the overall certainty for safety outcomes was relatively low. CONCLUSION: In CSU management, classical TCM formulas, particularly Danggui Yinzi, Yupingfeng powder, and Guizhi decoction, may improve remission and reduce recurrence when combined with sgAHs without increasing the incidence of AEs. Further high-quality head-to-head trials are needed to confirm these findings. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251022634.
引用
- Lv H, Zhu H, Mo H, et al. Chinese herbal formulas as adjuncts to antihistamines in chronic spontaneous urticaria: a network meta-analysis of efficacy, recurrence, and safety. Front Pharmacol. 2026. PMID: 42100312. doi:10.3389/fphar.2026.1718329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。